Prostate-specific antigen (PSA) testing, followed by biopsy if the PSA level is raised (typically ≥ PSA 3–4 ng/mL), is a widely accepted screening method for prostate cancer [1]. The gene discussed is KLK3; the disease is prostate cancer.